Relationship Between Serum β2-Microglobulin and Infiltration of CD8+ in the Tumor Tissue of Hodgkin's Lymphoma Patients

In newly diagnosed Hodgkin lymphoma patients, pre-treatment Beta-2 Microglobulin (B2M) levels will be measured. A thorough baseline assessment will be performed using CT imaging, and tumor tissue samples will be collected for Immunohistochemical (IHC) analysis to quantify CD8+ cell infiltration. Patients will be closely monitored throughout their treatment, with a follow-up CT scan at the end of therapy to evaluate therapeutic response. This study aims to investigate the correlation between pre-treatment B2M levels and CD8+ immune cell infiltration in tumor tissues, assessing their potential as predictive markers for chemotherapy response.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hodgkin Lymphoma Hemic and Lymphatic Diseases Hodgkin Disease Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Sex eligibility

All sexes

Study type

Observational

Primary location

Tishreen University

Latakia, Syria

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Newly diagnosed patients with Hodgkin lymphoma
No prior history of malignancy
Absence of primary or secondary immunodeficiencies

Exclusion criteria

Patients who have previously undergone treatment
Patients with acute or chronic infections
Patients with renal disorders
Individuals with autoimmune diseases
HIV-positive patients

Treatment and study plan

Primary outcomes

Therapeutic response

Time frame: 2-4 months

Achieving complete remission after chemotherapy

Sponsors and collaborators

Lead sponsor

Latakia University

Other

Registry information

Official study title

The Relationship Between Serum Beta-2 Microglobulin (sB2M) Levels and CD8+ Cell Infiltration in Hodgkin Lymphoma Tissues: Impact on Chemotherapy Outcomes

Important dates

Study start: 2024
Primary completion: 2024
Study completion: 2024
First posted: Aug 21, 2024
Registry last updated: Aug 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed